Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Ivacaftor therapy for cystic fibrosis
Susanna A. McColley
*
*
Corresponding author for this work
Pediatrics
Research output
:
Contribution to journal
›
Article
›
peer-review
2
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ivacaftor therapy for cystic fibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Area Cover
12%
Autosomal Recessive
12%
Bronchiectasis
12%
Clinical Trials
12%
Commercially Available
12%
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
62%
End-organ Damage
12%
Expert Opinion
12%
F508del
12%
Fibrosis Therapy
25%
G551D
12%
Genetic Disease
12%
Google Search
12%
Ivacaftor
100%
Life Shortening
12%
Lumacaftor
12%
MEDLINE
12%
Multisystem Disease
12%
Pancreatic Insufficiency
12%
Personalized Therapy
12%
Phase II Clinical Trial
12%
Phase III Clinical Trial
12%
Placebo-controlled Clinical Trial
12%
Pulmonary Function
12%
Quality of Life Assessment
12%
U.S. National Institutes of Health
12%
VX-770
12%
Medicine and Dentistry
Autosomal Recessive Inheritance
12%
Body Weight
12%
Bronchiectasis
12%
Clinical Trial
25%
Controlled Clinical Trial
12%
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
62%
End Organ Damage
12%
Genetic Disorder
12%
Ivacaftor
100%
Lifespan
12%
Lumacaftor
12%
Lung Function
12%
Pancreatic Insufficiency
12%
Personalized Medicine
12%
Placebo
12%
Quality of Life Measure
12%
Regulator Gene
12%
Systemic Disease
12%
Nursing and Health Professions
Body Weight
12%
Bronchiectasis
12%
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
62%
Genetic Disorder
12%
Ivacaftor
100%
Lumacaftor
12%
Medline
12%
National Health Organization
12%
Pancreatic Insufficiency
12%
Personalized Medicine
12%
Placebo
12%
Quality of Life Measure
12%
Systemic Disease
12%
Pharmacology, Toxicology and Pharmaceutical Science
Bronchiectasis
12%
Clinical Trial
25%
Controlled Clinical Trial
12%
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
62%
Genetic Disorder
12%
Ivacaftor
100%
Lumacaftor
12%
Pancreatic Insufficiency
12%
Placebo
12%
Systemic Disease
12%